Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
PF-06730512
BIOLOGICAL
2 trials
Sponsors
Pfizer
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Healthy
Phase 1
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512
Completed
NCT03146065
Pfizer
Healthy
Start: 2017-05-10
End: 2018-05-03
Updated: 2018-05-22
Phase 2
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
Terminated
NCT03448692
Pfizer
Focal Segmental Glomerulosclerosis (FSGS)
Start: 2018-10-15
End: 2023-02-14
Updated: 2024-04-18
Related Papers
A Phase 1 first‐in‐human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF‐06730512 in healthy participants
Pharmacology Research & Perspectives
2021-08-01
6 citations
PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis.
2021-04-03
13 citations